^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cyclophosphamide

    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    1d
    Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer (clinicaltrials.gov)
    P2, N=40, Completed, Beijing Wehand-Bio Pharmaceutical Co., Ltd | Phase classification: P1 --> P2
    Phase classification
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    paclitaxel • cyclophosphamide • epirubicin
    1d
    Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL (clinicaltrials.gov)
    P1, N=19, Recruiting, University Health Network, Toronto | Trial completion date: May 2026 --> Jun 2028 | Trial primary completion date: Mar 2026 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    1d
    Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Stanford University
    New P2 trial
    |
    TP53 (Tumor protein P53) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • MECOM (MDS1 And EVI1 Complex Locus) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    TP53 mutation
    |
    cyclophosphamide • fludarabine IV
    1d
    Retroperitoneal Malignant Triton Tumor in a 6-Year-Old Child Mimicking Wilms Tumor: A Case Report. (PubMed, Int Med Case Rep J)
    Despite palliative chemotherapy (cyclophosphamide and vincristine), the patient experienced rapid tumor recurrence and progressive clinical deterioration, culminating in death three weeks post-intervention. In resource-limited settings, where advanced molecular diagnostics are scarce, maintaining a high index of clinical suspicion and ensuring multidisciplinary management are paramount. Early histopathological confirmation is critical to addressing the rapid progression and therapeutic resistance characteristic of this malignancy.
    Journal
    |
    NF1 (Neurofibromin 1)
    |
    cyclophosphamide • vincristine
    1d
    Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=20 --> 9
    Enrollment closed • Enrollment change
    |
    clonoSEQ®
    |
    Opdivo (nivolumab) • Imbruvica (ibrutinib) • cyclophosphamide • Breyanzi (lisocabtagene maraleucel) • fludarabine IV
    1d
    Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, SWOG Cancer Research Network
    New P2 trial
    |
    CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A)
    |
    clonoSEQ®
    |
    cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • Revuforj (revumenib) • leucovorin calcium • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    1d
    Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer (clinicaltrials.gov)
    P2, N=182, Recruiting, Hebei Medical University Fourth Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • paclitaxel • Irene (pyrotinib) • cyclophosphamide • pegylated liposomal doxorubicin
    1d
    CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms (clinicaltrials.gov)
    P1, N=20, Recruiting, The General Hospital of Western Theater Command | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD70 (CD70 Molecule)
    |
    cyclophosphamide
    2d
    Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China | Initiation date: Mar 2026 --> Jul 2026
    Trial initiation date
    |
    CD19 (CD19 Molecule) • MPO (Myeloperoxidase)
    |
    cyclophosphamide • fludarabine IV
    2d
    Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET (clinicaltrials.gov)
    P3, N=379, Completed, Children's Oncology Group | Active, not recruiting --> Completed | Trial completion date: Jun 2028 --> Mar 2026
    Trial completion • Trial completion date
    |
    cisplatin • carboplatin • cyclophosphamide • vincristine • Neupogen (filgrastim)
    2d
    Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant (clinicaltrials.gov)
    P1, N=52, Active, not recruiting, City of Hope Medical Center | Suspended --> Active, not recruiting
    Enrollment closed
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    cyclophosphamide • etoposide IV • sirolimus • Kepivance (palifermin)
    3d
    A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) (clinicaltrials.gov)
    P2/3, N=960, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2/3 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD)